|API||Indication||Micronised / PSD||CEP||EU DMF||US DMF||JP DMF||KR DMF||CN DMF|
|Asenapine maleate p||Schizophrenia and acute mania||•|
|Eletriptan HBr p||Migraine||•||•|
|Olanzapine p||Schizophrenia, psychosis||•||•|
|Olanzapine pamoate||Schizophrenia, psychosis||•|
|Paliperidone palmitate||Schizophrenia, bipolar mania|
|Quetiapine hemifumarate p||Schizophrenia, psychosis||•||•||•|
|Risperidone p||Schizophrenia, psychosis||•||•||•||•|
|Rizatriptan benzoate p||Migraine||•||•||•|
P = Patent applications/granted patents owned by Neuraxpharm
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / INKE. All rights reserved.